X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (9) 9
oncology (9) 9
humans (8) 8
index medicus (8) 8
middle aged (8) 8
aged (7) 7
cancer (7) 7
chemotherapy (7) 7
adult (5) 5
bevacizumab (5) 5
clinical trials (5) 5
disease-free survival (5) 5
hematology, oncology and palliative medicine (5) 5
ovarian cancer (5) 5
ovarian neoplasms - pathology (5) 5
cancer therapies (4) 4
carcinoma (4) 4
neoplasm staging (4) 4
oncology, experimental (4) 4
research (4) 4
surgery (4) 4
treatment outcome (4) 4
aged, 80 and over (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
care and treatment (3) 3
cisplatin (3) 3
disease progression (3) 3
double-blind method (3) 3
expression (3) 3
iii trial (3) 3
italy (3) 3
neoplasm recurrence, local - pathology (3) 3
ovarian neoplasms - drug therapy (3) 3
paclitaxel - administration & dosage (3) 3
survival (3) 3
tumors (3) 3
young adult (3) 3
analysis (2) 2
anemia (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
carboplatin - administration & dosage (2) 2
carboplatin plus paclitaxel (2) 2
cervical cancer (2) 2
cohort studies (2) 2
drug administration schedule (2) 2
drug dosages (2) 2
follow-up studies (2) 2
hematology (2) 2
indoles - administration & dosage (2) 2
internal medicine (2) 2
medical prognosis (2) 2
medicine & public health (2) 2
metastasis (2) 2
motivation (2) 2
neoplasm recurrence, local - drug therapy (2) 2
ovarian neoplasms - mortality (2) 2
ovarian neoplasms - surgery (2) 2
platinum (2) 2
product development (2) 2
prognosis (2) 2
proportional hazards models (2) 2
quality of life (2) 2
risk assessment (2) 2
skin cancer (2) 2
studies (2) 2
survival rate (2) 2
time factors (2) 2
womens health (2) 2
1st-line treatment (1) 1
9,10-dimethyl-1,2-benzanthracene - adverse effects (1) 1
abdomen (1) 1
abridged index medicus (1) 1
accessory cells (1) 1
activation (1) 1
adenocarcinoma - etiology (1) 1
adenocarcinoma - prevention & control (1) 1
adenocarcinoma - veterinary (1) 1
adenocarcinoma, clear cell - genetics (1) 1
adenocarcinoma, clear cell - pathology (1) 1
adenocarcinoma, clear cell - surgery (1) 1
adenocarcinoma, mucinous - genetics (1) 1
adenocarcinoma, mucinous - pathology (1) 1
adenocarcinoma, mucinous - surgery (1) 1
adenosine diphosphate (1) 1
administration, oral (1) 1
adults (1) 1
alanine (1) 1
algorithms (1) 1
american women (1) 1
analysis of variance (1) 1
anemia - chemically induced (1) 1
angiogenesis (1) 1
angiogenesis inhibitors (1) 1
animals (1) 1
anogenital warts (1) 1
anogenital warts; cervical cancer; cin2-3; hpv; quality of life; tto; utilities (1) 1
anticancer properties (1) 1
anticoagulants (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 78 - 89
Summary Background Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor,... 
Hematology, Oncology and Palliative Medicine | BIBF 1120 | DES CANCERS | INTERGROUP TRIAL | LABEL DOSE-ESCALATION | CISPLATIN | ONCOLOGY | BEVACIZUMAB | TRIPLE ANGIOKINASE INHIBITOR | CARBOPLATIN PLUS PACLITAXEL | III TRIAL | MAINTENANCE THERAPY | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Diarrhea - chemically induced | Cytoreduction Surgical Procedures | Indoles - administration & dosage | Young Adult | Peritoneal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Carcinoma - pathology | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Peritoneal Neoplasms - pathology | Double-Blind Method | Carcinoma - surgery | Peritoneal Neoplasms - surgery | Anemia - chemically induced | Carboplatin - administration & dosage | Fallopian Tube Neoplasms - pathology | Thrombocytopenia - chemically induced | Disease Progression | Disease-Free Survival | Indoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fallopian Tube Neoplasms - surgery | Intention to Treat Analysis | Aged | Neoplasm Staging | Ovarian Neoplasms - surgery | Clinical trials | Chemotherapy | Hospitals | Growth factors | Cancer | Ovarian cancer | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 396 - 405
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 10, pp. 943 - 949
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1137 - 1146
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 561 - 568
Journal Article
by Coleman, Robert L and Oza, Amit M and Lorusso, Domenica and Aghajanian, Carol and Oaknin, Ana and Dean, Andrew and Colombo, Nicoletta and Weberpals, Johanne I and Clamp, Andrew and Scambia, Giovanni and Leary, Alexandra and Holloway, Robert W and Gancedo, Margarita Amenedo and Fong, Peter C and Goh, Jeffrey C and O'Malley, David M and Armstrong, Deborah K and Garcia-Donas, Jesus and Swisher, Elizabeth M and Floquet, Anne and Konecny, Gottfried E and McNeish, Iain A and Scott, Clare L and Cameron, Terri and Maloney, Lara and Isaacson, Jeff and Goble, Sandra and Grace, Caroline and Harding, Thomas C and Raponi, Mitch and Sun, James and Lin, Kevin K and Giordano, Heidi and Ledermann, Jonathan A and Buck, M and Dean, A and Friedlander, M L and Goh, J C and Harnett, P and Kichenadasse, G and Scott, C L and Denys, H and Dirix, L and Vergote, I and Elit, L and Ghatage, P and Oza, A M and Plante, M and Provencher, D and Weberpals, J I and Welch, S and Floquet, A and Gladieff, L and Joly, F and Leary, A and Lortholary, A and Lotz, J and Medioni, J and Tredan, O and You, B and El-Balat, A and Hänle, C and Krabisch, P and Neunhöffer, T and Pölcher, M and Wimberger, P and Amit, A and Kovel, S and Leviov, M and Safra, T and Shapira-Frommer, R and Stemmer, S and Bologna, A and Colombo, N and Lorusso, D and Pignata, S and Sabbatini, R F and Scambia, G and Tamberi, S and Zamagni, C and Fong, P C and O'Donnell, A and Gancedo, M Amenedo and Herraez, A Casado and Garcia-Donas, J and Guerra, E M and Oaknin, A and Palacio, I and Romero, I and Sanchez, A and Banerjee, S N and Clamp, A and Drew, Y and Gabra, H G and Jackson, D and Ledermann, J A and McNeish, I A and Parkinson, C and Powell, M and Aghajanian, C and ... and ARIEL3 investigators and ARIEL3 Investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10106, pp. 1949 - 1961
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | SOLID TUMORS | BEVACIZUMAB | OPEN-LABEL | CANCER | HETEROZYGOSITY | EPITHELIAL OVARIAN | CHEMOTHERAPY | Double-Blind Method | Follow-Up Studies | Risk Assessment | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Survival Rate | Treatment Outcome | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Indoles - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Maintenance Chemotherapy - methods | Internationality | Ovarian Neoplasms - therapy | Female | Aged | Molecular Targeted Therapy - methods | Clinical trials | Care and treatment | Carcinoma | Drug therapy | Ovarian cancer | Cancer | Analysis | Chemotherapy | Ovarian carcinoma | Platinum | Biomarkers | Mutation | Cancer therapies | Evidence-based medicine | Tumors | Homologous recombination | Central nervous system | Poly(ADP-ribose) | Homology | Genomes | Fallopian tube | Anticancer properties | Metastases | Homologous recombination repair | Randomization | Pain | Motivation | Ribose | Hemoglobin | Alanine | Anemia | Poly(ADP-ribose) polymerase | Adenosine diphosphate | Breast cancer | Patients | Survival | Heterozygosity | Abdomen | Polymerase | Inhibitors | Point mutation | Loss of heterozygosity | Antitumor activity | Aspartate aminotransferase | Peritoneum
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2011, Volume 33, Issue 8, pp. 1084 - 1095.e4
Journal Article
International Journal of Cancer, ISSN 0020-7136, 12/2010, Volume 127, Issue 12, pp. 2749 - 2757
Medulloblastoma (MB) is the most common pediatric tumor of the CNS, representing ∼20% of all childhood CNS tumors. Although in recent years many molecular... 
IGF‐I | ERβ | Ptch1 | ERα | radiation | IGF-I | Radiation | SONIC HEDGEHOG | ADULTS | ER beta | BRAIN-TUMORS | ESTROGEN-RECEPTOR-BETA | ONCOLOGY | BASAL-CELL CARCINOMA | PEDIATRIC MEDULLOBLASTOMA | DNA-REPAIR | EXPRESSION | ER alpha | GROWTH-FACTOR-I
Journal Article
Oncology, ISSN 0030-2414, 09/2004, Volume 67, Issue 2, pp. 103 - 111
Objective: We have updated our findings on the efficacy of concomitant radiochemotherapy plus radical surgery in a larger series of patients (n = 54) with... 
Clinical Study | Neoadjuvant radiochemotherapy | Cyclooxygenase-2 status | Locally advanced cervical cancer | HYSTERECTOMY | neoadjuvant radiochemotherapy | PELVIC RADIATION | cervical cancer | RADIATION-THERAPY | RADICAL SURGERY | CISPLATIN | ONCOLOGY | CONCURRENT CHEMOTHERAPY | CHEMORADIATION | locally advanced | RADIOTHERAPY | cyclooxygenase-2 status | CARCINOMA | EXPRESSION | Immunohistochemistry | Isoenzymes - analysis | Lymph Node Excision | Predictive Value of Tests | Prognosis | Prostaglandin-Endoperoxide Synthases - analysis | Cyclooxygenase 2 | Humans | Middle Aged | Uterine Cervical Neoplasms - pathology | Cisplatin - administration & dosage | Fluorouracil - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Radiotherapy Dosage | Uterine Cervical Neoplasms - enzymology | Uterine Cervical Neoplasms - radiotherapy | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Hysterectomy - methods | Proportional Hazards Models | Uterine Cervical Neoplasms - surgery | Logistic Models | Treatment Outcome | Uterine Cervical Neoplasms - drug therapy | Membrane Proteins | Disease-Free Survival | Analysis of Variance | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - methods | Aged | Neoplasm Staging | Radiology | Chemotherapy | Surgery | Cervical cancer | Clinical outcomes
Journal Article